Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profile of IL33 & PD1-treated ILC2 from KPC tumor-bearing mice

ABSTRACT: We investigated the genetic profiles of IL33 and PD1-treated group 2 innate lymphoid cells (ILC2) harvested from KPC tumors and draining lymph nodes in a pancreatic ductal adenocarcinoma (PDAC) mouse model.

ORGANISM(S): Mus musculus

PROVIDER: GSE136720 | GEO | 2019/09/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional profile of IL33 & PD1-treated ILC2 from KPC tumor-bearing mice

Project description:Transcriptional profile of IL33 & PD1-treated ILC2 from KPC tumor-bearing mice

| PRJNA563328 | ENA

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190103 | GEO

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:We report the RNAseq of mouse pancreatic cancer cell lines with Kras ON vs Kras OFF. TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190468 | GEO

Transcriptomic analysis (RNAseq) of tumour-exposed Tregs from IL33 genetical deficient mice

Project description:Our purpose was to analyse the transcriptomic profile of Tregs from tumor-draining lymph nodes of melanoma-bearing mice in order to understand the functional difference between WT and il33-/- Tregs

2019-10-16 | GSE138872 | GEO

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and regulation of IL33 via Alu elements

Project description:Idiopathic pulmonary fibrosis (IPF) causes remodelling of distal lung, leading to respiratory failure. Pulmonary remodelling is characterised histologically not only by fibrosis but by also appearance of basal cells, yet the involvement of basal cells to IPF pathogenesis remains unclear. Here, we focus on the long non-coding RNA MIR205HG highly expressed in basal cells by single-cell RNA sequencing, to elucidate their role in IPF. Through RNA sequencing of genetic manipulations using primary cells and IPF-derived airway organoids, we uncovered MIR205HG to regulate IL33 expression. Mechanistically, the AluJb element of MIR205HG plays a key role in IL33 expression. In addition, we successfully identified a small molecule that targets this AluJb element and decreases IL33 expression. IL33 is known to induce ILC2, and MIR205HG expression positively correlated with the number of ILC2 in IPF patients. Collectively, these findings provide insights into the contributing mechanisms of basal cells to IPF and potential therapeutic targets.

2025-03-10 | GSE283175 | GEO

Transposition of native chromatin (ATACseq) of tumour-exposed Tregs from IL33 genetical deficient mice

Project description:Our purpose was to analyse the chromatin landscape of Tregs from tumor-draining lymph nodes of melanoma-bearing mice in order to understand the functional difference between WT and il33-/- Tregs

2019-10-16 | GSE138871 | GEO

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and regulation of IL33 via Alu elements (part 4)

2025-03-10 | GSE275720 | GEO

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and regulation of IL33 via Alu elements (part 3)

2025-03-10 | GSE275717 | GEO

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and regulation of IL33 via Alu elements (part 2)

2025-03-10 | GSE275709 | GEO

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and regulation of IL33 via Alu elements (part 1)

2025-03-10 | GSE275700 | GEO